Review
Jul 2026
Recent advances in 1,3,5-triazine-based PI3K inhibitors for cancer therapy: a comprehensive review.
This comprehensive review critically summarizes advances from 2021-2025 in the design of selective PI3K inhibitors based on the 1,3,5-triazine (s-triazine) scaffold, emphasizing how its symmetric 2/4/6 substitution vectors, electron-deficient hinge-binding profile, and modular cyanuric chloride - enabled SNAr synthesis accelerate structure - activity relationship (SAR) optimization.
Utkarsha Kulkarni, Adarsh Yadav, Princy Desai et al.
· Future Medicinal Chemistry · 0 citations